Current Highlight from February 14, 2014
Age, Sex, and Tissue Differences in Gene Expression in the Rat
The Sequencing Quality Control Consortium, a large international effort led by NCTR scientists, generated a comprehensive gene expression atlas using next-generation sequencing technology. This technology catalogues variations in gene expression in 11 tissues at four developmental stages of male and female rats. The web-based, publicly-available Rat BodyMap database
is expected to provide a comprehensive platform for biomedical research. The database is also expected to increase understanding of disease, drug efficacy, and toxicity in the rat model and ultimately improve the translation of preclinical findings to humans. This study was partially supported by the FDA Office of Women’s Health and is published inNature Communications (2014, 5:3230).
is expected to provide a comprehensive platform for biomedical research. The database is also expected to increase understanding of disease, drug efficacy, and toxicity in the rat model and ultimately improve the translation of preclinical findings to humans. This study was partially supported by the FDA Office of Women’s Health and is published inNature Communications (2014, 5:3230).For additional information, please contact James Fuscoe, Ph.D., Personalized Medicine Branch, Division of Systems Biology, FDA/NCTR, or Weida Tong, Ph.D., Director, Division of Bioinformatics and Biostatistics, FDA/NCTR.
Potential New Biomarkers of Drug-Induced Liver Injury (DILI)
NCTR scientists have published a review article in Toxicology Letters (2014, 225:401-406) that summarizes the issues surrounding the potential utility of blood and urine extracellular vesicle (EV)-based biomarkers for detection of drug hepatotoxicity. These circulating EVs are membrane-surrounded structures that contain molecules (mRNA, miRNA, and protein) that can be indicative of drug hepatotoxicity. Although recent evidence suggests these EV-based biomarkers may be more liver-specific and more informative about the offending drugs than are conventional biomarkers, a lack of standardized EV isolation methods and analytic approaches currently limits their regulatory and clinical utility.
(2014, 225:401-406) that summarizes the issues surrounding the potential utility of blood and urine extracellular vesicle (EV)-based biomarkers for detection of drug hepatotoxicity. These circulating EVs are membrane-surrounded structures that contain molecules (mRNA, miRNA, and protein) that can be indicative of drug hepatotoxicity. Although recent evidence suggests these EV-based biomarkers may be more liver-specific and more informative about the offending drugs than are conventional biomarkers, a lack of standardized EV isolation methods and analytic approaches currently limits their regulatory and clinical utility. For additional information, please contact Qiang Shi, Ph.D., Innovative Safety and Technologies Branch, Division of Systems Biology, FDA/NCTR, or Donna Mendrick, Ph.D., Director, Division of Systems Biology, FDA/NCTR.
.png)
No hay comentarios:
Publicar un comentario